Portfolios Sustainability Therapy 
Spa Executive
MARCH 17, 2025
In this role, he spearheads the development and implementation of innovative wellness strategies across Banyan Groups diverse portfolio of luxury resorts, spas, and wellbeing experiences. PH: As Director of Integrated Wellbeing, I lead the strategic vision and execution of the Groups wellbeing portfolio.
The Dermatology Digest
FEBRUARY 21, 2025
The deal strengthens Cosettes dermatology and womens health businesses, expands Cosettes commercial and operational capabilities, and adds multiple sustainable and growing patent-protected products. Together, we will extend the reach of important therapies, drive innovation, and improve patient access.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Spa Executive
JULY 17, 2024
A growing consumer demand for sustainable and health-focused travel options is pushing the hospitality industry to innovate and prioritize wellness to meet these evolving expectations. Another critical challenge is navigating the balance between sanitation and sustainability.
Spa Executive
NOVEMBER 10, 2023
As global vice president of wellbeing, she will develop and deepen the wellness experience across Auberge Resorts Collection’s portfolio. Under the mentorship of Susan Harmsworth, she honed her skills in areas like spa therapies, aromatherapy, wellness operations, design, marketing, and public relations.
Spa Executive
JANUARY 16, 2024
The role of Vice President of Wellbeing is new for the brand, but an essential step in Jumeirah Group’s journey as they continue to invest in advancing the wellbeing offering through new concepts, therapies, and partnerships, which are all designed to enrich the wellness experience of guests.
Spa Executive
JUNE 19, 2024
Managing an extensive portfolio of more than 120 hotels, including 26 major brands and 19 boutique properties, Remington has positioned itself as a leader in the hospitality industry. Strategic initiatives include enhancing operational efficiency, integrating advanced technologies, and prioritizing sustainability practices.
The Dermatology Digest
MARCH 5, 2024
Pharmacokinetic (PK) data showed a half-life of approximately 75 days across doses tested and pharmacodynamic (PD) data showed, deep and sustained inhibition of key atopic dermatitis (AD) biomarkers pSTAT6 and TARC for ~3 months (longest follow-up available, with inhibition still ongoing at time of the data cut).
Expert insights. Personalized for you.
52 
Let's personalize your content